Radotinib
As of the edition of 20 October 2026, Radotinib is a small molecule: marketed, first approved in 2012 (KR); acts on ABL1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2012
- Kind
- Small molecule
- First approved
- 5 January 2012 (KR)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- IL-Yang
- Registered trials
- 7, 0 stopped early
- Disease areas
- Blood and lymph; Cancer; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ABL1 | Tyrosine-protein kinase ABL1 | P00519 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 2 | 3 | 1 | 1 | 0 |
| Phase 3 | 3 | 1 | 2 | 0 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Il-Yang Pharm | Lead sponsor of trials | 2008 to now |